SUPN - Adamas Pharmaceuticals: An Acceptable Buyout At The Perfect Time

• Adamas Pharmaceuticals announced that Supernus Pharmaceuticals has struck a deal to buy ADMS at $8.10 per share with CVR kickers. I believe this is a perfect time for both companies.
• Supernus' leading product, Trokendi, is moving closer to its patent expiration in 2023. GOCOVRI might help plug the hole.
• Adamas investors might not be getting a premium price for their shares, but the buyout could be a savior for longstanding ADMS investors.
• The ADMS deal has enticed me to consider a position in SUPN. I discuss my plans for potentially establishing a pilot position in the near-term.

For further details see: